Jun 1, 2023

Coave Reports Encouraging Phase 1/2 Clinical Trial Results for PDE6B Gene Therapy

Eye On the Cure Research News

The company is expanding the trial to enroll younger patients with less advanced disease

Get updates on Eye On the Cure Research News

Coave Therapeutics, a French biotechnology company, announced that its gene therapy for people with retinitis pigmentosa (RP) caused by mutations in the gene PDE6B improved visual function at 12 months after dosing for a subgroup of six patients with less-advanced disease in a 17-patient, Phase 1/2 clinical trial.

The company said the results support preparation for a registrational trial for the PDE6B gene therapy. With success in a registrational or pivotal trial, the company would likely seek marketing approval from regulators such as the European Medicines Agency and/or the US Food & Drug Administration.

Coave has received approval from regulators to dose six additional patients, ages 13 to 25 years of age with less-advanced disease, in the current Phase 1/2 clinical trial.

Improvements for the trial subgroup were reported in: best-corrected visual acuity (BCVA); visual fields; microperimetry which measures sensitivity in the central retina; full-field sensitivity (FST), which measures general retinal sensitivity; and the ability to navigate a mobility course.

Two dose levels of the gene therapy were evaluated in the Phase 1/2 clinical trial. Only the patient’s worse-seeing eye was treated. Those patients with improved visual function received the higher dose.

Known as CTx-PDE6B, the gene therapy is administered by an injection underneath the retina. The gene therapy uses a human-engineered adeno-associated virus (AAV) to deliver copies of healthy PDE6B genes to the photoreceptors in the retina to augment the mutated gene copies.